Rosuvastatin as an affordable medicine for effective prevention of cardiovascular diseases

T.E. Kolmakova, I.A. Alexeeva, M.V. Ezhov

National Medical Research Center of Cardiology, Moscow

According to the latest ESC (European Society of Cardiology) Guidelines on dyslipidemia management for the prevention of cardiovascular diseases, low-density lipoprotein (LDL) cholesterol is the only causative risk factor for the development of atherosclerosis complications. In everyday clinical practice, the target level of LDL cholesterol is rarely achieved, which is especially important for high-risk patients of cardiovascular complications. In comparison with other statins, rosuvastatin is already most effective in initial doses and has a better safety profile. Lower all-cause mortality has been shown in patients receiving rosuvastatin versus those treated with other statins. Besides, the significant effect of rosuvastatin was observed in patients with metabolic syndrome, type 2 diabetes mellitus; reduction in the risk of cardiovascular complications in patients with arterial hypertension was also noted. Thera py with rosuvastatin has shown the reduction of complications risk in patients without cardiovascular diseases but with a moderate risk of their occurrence.

Keywords: dyslipidemia, low-density lipoprotein cholesterol, rosuvastatin, efficacy, safety, generics.

For citation: Kolmakova T.E., Alexeeva I.A., Ezhov M.V. Rosuvastatin as an affordable medicine for effective prevention of cardiovascular diseases. RMJ. 2020;10:20–24.